The mechanism of increased cardiac risk attributable to depressive illness is at present uncertain, but activation of the sympathetic nervous system, exaggerated platelet reactivity and/or enhanced inflammatorymediated atherogenesis are likely to be of prime importance. [11] [12] [13] [14] [15] Whole body sympathetic nervous system activity seems to be elevated in patients with major depression. 11, 12 In a range of clinical contexts stimulation of the cardiac sympathetic outflow has been demonstrated to contribute to myocardial infarction, ventricular arrhythmias and sudden death. Indeed, activation of the sympathetic outflow to the heart is common in patients unexpectedly developing ventricular tachycardia and ventricular fibrillation outside hospital. 16 In heart failure there is similarly a high level of stimulation of the cardiac sympathetic nerves, which has been directly linked to the development of ventricular arrhythmias and sudden death. 17 Activation of platelets is pivotal in the development of haemostasis and thrombosis, and plays a role in the development of atherosclerosis. Patients with depressive illness exhibit enhanced baseline platelet activation and responsiveness 13 and elevated platelet factor 4 and ␤-thromboglobulin plasma levels have been described in depressed patients with ischemic heart disease. 18 It would seem that increased susceptibility to platelet activation may be the mechanism by which depression is a significant risk factor for the development of ischaemic heart disease and could account for the increased mortality observed in patients developing depression following myocardial infarction.
Given reports documenting elevated plasma cytokine concentrations in patients with major depression, 14, 19, 20 the recent demonstration that acute inflammation upregulates cytokine-stimulated sphingomyelinase may provide further insight into the etiology of depressionassociated cardiac risk. 15 Atherosclerotic lesions contain extracellular sphingomyelinase activity with the ability to hydrolyze the sphingomyelin of subendothelial low density lipoprotein and may promote atherosclerosis by enhancing subendothelial low density lipoprotein retention and aggregation, and foam cell formation. 21 Despite this growing body of evidence linking depressive illness, cardiovascular risk and mortality, individuals who develop depression are frequently not diagnosed and hence may remain untreated. 22 Herein lies the tragedy, for depression is a treatable condition and there exists an array of effective therapies capable of alleviating symptoms and improving quality of life. The recent demonstration of the safety of sertraline administration in patients following acute myocardial infarction 23 holds further promise for the treatment of depression in the cardiology setting. Clearly, identifying the underlying neurochemical mechanisms responsible for alterations in affective behaviour and testing whether pharmacologial interventions can modify brain neurotransmitter turnover and reduce cardiac risk will be an important step forward in alleviating the burden of depressive illness in the community. 
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